Stem Cell Ophthalmology Treatment Study II

Inclusion Criteria:

• Have objective, documented damage to the retina or optic nerve unlikely to improveOR

• Have objective, documented damage to the retina or optic nerve that is progressiveAND have less than or equal to 20/30 best corrected central visual acuity in one orboth eyes AND/OR an abnormal visual field in one or both eyes.

• Be at least 3 months post-surgical treatment intended to treat any ophthalmologicdisease and stable.

• If under current medical therapy ( pharmacologic treatment) for a retinal or opticnerve disease be considered stable on that treatment and unlikely to have visualfunction improvement ( for example, glaucoma with intraocular pressure stable ontopical medications but visual field damage ).

• Have the potential for improvement with BMSC treatment and be at minimal risk of anypotential harm from the procedure.

• Be over the age of 18

• Be medically stable and able to be medically cleared by their primary care physicianor a licensed primary care practitioner for the procedure.

• Medical clearance means that in the estimation of the primary care practitioner, thepatient can reasonably be expected to undergo the procedure without significantmedical risk to health.

Exclusion Criteria:

• Patients who are not capable of an adequate ophthalmologic examination or evaluationto document the pathology.

• Patients who are not capable or not willing to undergo follow up eye exams with theprinciple investigator or their ophthalmologist or optometrist as outlined in theprotocol.

• Patients who are not capable of providing informed consent.

• Patients who may be at significant risk to general health or to the eyes and visualfunction should they undergo the procedure.